DIRECT-TO-CONSUMER ADVERTISING (DTCA) IS LEgal only in the United States and New Zealand and has been linked with drug overutilization, public health concerns, and higher costs. Despite global proscriptions, DTCA is the most rapidly increasing form of pharmaceutical marketing, with approximately $4 billion in US expenditures, outpacing physician marketing and research and development. The Internet has rapidly developed, with users moving from passive information using read-only “Web 1.0” technology to interactive tailored relationships using “Web 2.0” technology. This includes social networking sites and other interactive systems, resulting in new online DTCA marketing opportunities that transcend geopolitical borders. Currently, the US Food and Drug Administration (FDA) has not issued guidelines on this form of DTCA marketing. Yet electronic DTCA with Web 2.0 technology already has the potential for significant presence and may have unrealized public health effects.
[1]
B. Kuehn.
FDA weighs limits for online ads.
,
2010,
JAMA.
[2]
T. Mackey,et al.
Searching for Safety: Addressing Search Engine, Website, and Provider Accountability for Illicit Online Drug Sales
,
2009,
American Journal of Law & Medicine.
[3]
R. Sindwani,et al.
Pharmaceutical Marketing and the New Social Media
,
2011
.
[4]
S. Morgan,et al.
Twelve Years' Experience with Direct-to-Consumer Advertising of Prescription Drugs in Canada: A Cautionary Tale
,
2009,
PloS one.
[5]
R. Kravitz,et al.
A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising.
,
2010,
American journal of public health.